CutPRO® Cut Resistant Clothing Sponsoring Leading Glass Event ‘Glass Focus 2019’
19.11.2019 11:00:00 EET | Business Wire | Press release
British firm CutPRO® is sponsoring this year’s ‘Glass Focus 2019’ event taking place on 21 November in Sheffield, United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005029/en/
CutPRO® is a pioneering British brand of high performance cut resistant clothing, providing fully CE certified, EN 388:2016 tested and thoroughly field tested cut protection. (Graphic: Business Wire)
Robert Kaiser, CEO of PPSS Group, the firm behind the CutPRO® brand, also announced it had entered the ‘Health and Safety Action’ category: “We have high hopes to win this prestigious award. Our innovative and pioneering brand of high performance cut resistant clothing somewhat deserves that level of recognition”.
The event is organised by ‘British Glass’, the representative body for the UK industry. Communicating the glass sector’s values and interests, their aim is to secure a thriving and sustainable future.
UK based PPSS Group has been producing cut resistant clothing for the past ten years, its sole purpose being the protection of frontline professionals in sectors where cuts and lacerations are a high risk e.g. homeland security.
In February 2018 the now highly acclaimed CutPRO® brand was launched, again using their very own Cut-Tex® PRO cut resistant fabric. Cut-Tex® PRO has achieved outstanding levels of cut, tear, abrasion and puncture resistance, while being extremely durable, lightweight and rather comfortable.
As a single layer it is offering ANSI/ISEA 2016 Blade Cut Resistance Level A5.
CutPRO®s Senior Product Consultant Eve Ichim operated as a liaison between potential customers and the firm’s production team, gathering relevant information about precise requirements and preferences for cut resistant clothing.
Based on this information, extensive market research and working together with the multi-award-winning Department of Apparel from one UK’s leading Universities, CutPRO® is now offering the ultimate garment designs, taking 'durability' and 'quality' to a completely different level.
All garments are manufactured in the E.U. and are fully CE marked and certified (Cat II PPE). This means they fully comply with European laws, rules and regulations.
All garments have also been successful assessed against the updated and latest EN 388:2016 standard, confirming the following performance levels: Cut Resistance Level E (Level 5 on previous standard). Puncture Resistance Level 4. Tear Resistance Level 4. Abrasion Resistance Level 3.
If you are planning to attend the ‘Glass Focus 2019’ go and say hi to their team. You will be welcomed with open arms and an immense level of technical knowledge.
Robert Kaiser has also recently announced his company’s participation at next year’s glasstec2020 Expo in Dusseldorf, Germany:
"We have decided to present and exhibit our truly outstanding cut resistant clothing range at glasstec2020, the world’s largest and most respected Exhibition within the glass industry."
"There is no better platform for us to showcase our range of potentially lifesaving cut resistant garments to the world."
In case you have any questions in reference to cut resistant clothing, please email info@cut-pro.com or visit www.cut-pro.com.
END
About CutPRO®
CutPRO® Cut Resistant Clothing is a pioneering brand of highly protective clothing. Made from the world’s most reliable, fully certified and thoroughly field-tested cut resistant fabric Cut-Tex® PRO. The company’s social media presence: Facebook, LinkedIn, Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005029/en/
Contact information
Ryan Vickers, CDO
PPSS Group / CutPRO®
info@ppss-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom